UK health minister: Lilly weight-loss drug could help thousands

Eli Lilly's new weight-loss treatment, approved by the British health regulator on Wednesday, has the potential to benefit thousands of obese Britons and could help the state-run National Health Service save billions of pounds, the health secretary said. U.S. and UK regulators on Wednesday gave the thumbs up to Lilly's weight-loss treatment Zepbound, also known as Mounjaro or tirzepatide, paving the way for a powerful new rival to Novo Nordisk's Wegovy in addressing record obesity rates. "Mounjaro has the potential to help thousands of people living with obesity and support those suffering from weight-related illnesses – if used alongside diet and physical activity," Health Secretary Steve Barclay said in a statement.